Antibody drugs appear effective. Now can we make enough of them?

VincenzoRusso,aresearcheratRegeneron,workstoisolateviralDNAclonesofSARS-CoV-2.EricaYoonforSTATTheCov AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons




hotspot

author：knowledge    Page View：63
Franklin faces
Adobe

ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

advertisement

Arch declined to comment on the new fundraising.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In
Previous article： Readout Newsletter: The latest on Moderna, Apellis, and Merck
Next article： State Dept. review finds Biden bears some blame for Afghanistan failures